We investigate the role of axial ligands on the near-IR-optical and paramagnetic NMR spectra of the complex [YbL](+3) where L is the stereodefined enantiopure chiral macrocycle (L = hexaazapentacyclo[25.3.1.1(12,24).0(4,9).0(19,24)]dotriaconta-1(31),2,10,12,14,16(32),17,25,27,29-decaene). The conformation in solution of the lanthanide complex is characterized by analyzing the pseudocontact 1H NMR shifts and is consistent with X-ray data of single crystal of analogue systems. The macrocycle is confined within a thin equatorial disk, leaving the cation open to at least two axial sites, on the opposite hemispheres. We recorded, assigned, and analyzed the 1H NMR spectra of several species upon changing the anion in solution, calculating the magnetic susceptibility anisotropy tensor for each. Near-IR circular dichroism is used to investigate the solution equilibria involving the competing ligands and to derive a spectroscopic series for Yb.

The interaction between quercetin, a popular antioxidant flavonoid, and human serum albumin (HSA) is investigated and characterized by means of induced circular dichroism and saturation transfer difference NMR. These techiques demonstrate the reversible binding of quercetin to the carrier protein, which is responsible for its dissolution in aqueous medium. Competition experiments with two classical probes for HSA binding sites, namely Ibuprofen and Warfarin (a common anticoagulant coumarin), demonstrate that quercetin has a primary binding site located in the subdomain IIA, where coumarins are hosted. The affinity for this site is large and we found that quercetin may effectively displace warfarin from HSA. This may have relevant consequences in rationalizing the interferences of common dietary compounds and food supplements to anticoagulant treatments.

A structural study of metal ion adducts of a new anthracycline disaccharide (MEN 10755) was undertaken.

No abstract

No abstract

Background: Primary (PID) or secondary (SID) immunodeficiencies are diseases caused by quantitative and/or functional alterations of the different mechanisms involved in the innate and adaptive immune response. This economic evaluation was conducted to compare the cost of treatment of HYQVIA® (hyaluronidase-facilitated subcutaneous infusion of immunoglobulin, fSCIG) compared to intravenous immunoglobulin (IVIG) or subcutaneous immunoglobulin (SCIG), currently reimbursed in Italy, in the treatment of PIDs or SIDs. Methods: A cost-minimisation analysis was carried out, considering the hospital’s perspective. The direct medical costs (cost of immunoglobulins and cost of administration) were assessed. The analysis was conducted considering one year (52 weeks) time horizon. The reference population included adult patients with PID with impaired antibody production or adult patients with SID with severe or recurrent infections, ineffective antimicrobial treatment and documented specific antibody defect (PSAF) or serum IgG level < 4 g/L. Results: In the maintenance treatment of PID, HYQVIA® (€ 20,020.00) was the therapeutic alternative with the lowest mean annual cost compared to HIZENTRA® (€ 22,165.19) and VENITAL® (€ 24,967.68). Moreover, in the maintenance treatment of SIDs, HYQVIA® (€ 17,160.00) was the cost-saving therapeutic alternative compared to VENITAL® (€ 22,107.68). A sensitivity analysis confirmed the base case results. Conclusion: Due to lower costs of administration and different scheme of administration, HYQVIA® was a cost-saving alternative to SCIG e IVIG in the treatment of PID and to IVIG in the treatment of SID